Publications by authors named "E Ratti"
Article Synopsis
- - The study examines the drug luvadaxistat, a DAAO inhibitor that increases d-serine levels, aimed at treating negative symptoms of schizophrenia through enhanced NMDAR signaling. - Conducted in a randomized, placebo-controlled format, the INTERACT trial included 256 participants and showed no significant improvement in negative symptoms after 12 weeks, but some cognitive enhancements with the 50 mg dose were noted. - Luvadaxistat was well-tolerated with no new safety concerns, indicating potential for further research, particularly regarding its effects on cognitive impairment in schizophrenia patients.
What Do We Teach to Engineering Students: Embedded Ethics, Morality, and Politics.
Sci Eng Ethics
February 2024
In the past few years, calls for integrating ethics modules in engineering curricula have multiplied. Despite this positive trend, a number of issues with these 'embedded' programs remains. First, learning goals are underspecified.
View Article and Find Full Text PDFIn Alzheimer's disease, the spread of aberrantly phosphorylated tau is an important criterion in the Braak staging of disease severity and correlates with disease symptomatology. Here, we report the results of TANGO ( NCT03352557 ), a randomized, double-blind, placebo-controlled, parallel-group and multiple-dose long-term trial of gosuranemab-a monoclonal antibody to N-terminal tau-in patients with early Alzheimer's disease. The primary objective was to assess the safety and tolerability of gosuranemab compared to placebo.
View Article and Find Full Text PDF